Description

Exemestane 25 mg

Marque : Magnus Pharmaceuticals
Contenu : 30 tablets | 25 mg per tablet
Prix : €38
Fabriqué en : L'Europe

🧪 Aperçu du produit

Exemestane 25 mg is a third-generation, steroidal aromatase inhibitor (AI) that irreversibly binds the CYP19 enzyme, producing sustained suppression of systemic estrogen. Widely used in hormonal modulation and post-cycle therapy (PCT) research, it is particularly effective for testosterone-boosting protocols and estrogen-dependent tumor investigations.

A single 25 mg dose lowers estradiol by 60–80% within 12 hours and sustains suppression for up to 48 hours due to its ~24–27 hour half-life. Studies confirm its effectiveness in raising LH, FSH, and modestly increasing endogenous testosterone without altering adrenal androgens. This compound is listed on WADA’s S4 prohibited list for hormone modulators.

✅ Principaux résultats de la recherche

Irreversible aromatase blockade:
Covalently deactivates CYP19, maintaining estrogen suppression post-clearance [ScienceDirect]

24-hour pharmacokinetics:
Half-life of 24–27 hours ensures stable once-daily dosing in long-term hormonal protocols [PubMed]

↑ Testosterone-to-estradiol ratio:
25 mg/day improved T:E ratios in male models without affecting DHEA/androstenedione [FDA data]

Bone & lipid impact (chronic use):
Long-term data show ↓ BMD and HDL↓ / LDL↑ — relevant for extended-duration studies [PubMed, PMC]

Shelf-stable & lab-friendly:
Film-coated tablets remain potent at ≤25 °C without refrigeration [ICH Stability, MSDS]

🧬 Applications suggérées en laboratoire

Irreversible aromatase inhibition and estrogen-suppression modeling
Testosterone enhancement in male hypogonadism models
PCT studies for anabolic-recovery protocols
LH/FSH modulation research
Tamoxifen-resistant estrogen-tumor studies

📊 Spécifications techniques

Champ d'application	Données
Nom chimique	Exemestane (INN)
Formule chimique	C<sub>20</sub>H<sub>24</sub>O<sub>2</sub>
Synonymes	Aromasin; FCE 24304; 6-methyleneandrosta-1,4-diene-3,17-dione
Poids moléculaire	296.4 g/mol
Numéro CAS	107868-30-4
Demi-vie	~24–27 hours
Fenêtre de détection	Medium-long, varies with protocol
Avantages documentés	↓ E2 by 60–80%, ↑ LH/FSH, ↑ T, stable estrogen suppression
Principaux risques	↓ BMD, lipid shifts, fatigue, joint pain, hot flashes
Composé actif total	750 mg per carton (25 mg × 30 tablets)
Durée de conservation	36 months (manufacturer specification)

❄️ Perspectives de recherche soutenues par PubChem

Irreversible suppression of estrogen via steroidal aromatase inhibition
Rapid E2 reduction within 12 hours of dosing
Increases T:E ratio in male subjects without disturbing adrenal steroids
Maintains hormonal control for up to 48 hours post-dose
Applied in resistant ER+ tumor model studies and androgen support trials

⚠️ Effets secondaires documentés par la recherche

Common: Hot-flushes, arthralgia, fatigue, insomnia
Long-term: Bone mineral density reduction, HDL↓/LDL↑
Other: Menopausal symptoms and mood variations
Listed under WADA S4 — prohibited in all competitive levels

🧯 Manipulation et conformité

Réservé à la recherche — Not for human or veterinary use
Store at 15–25 °C, protect from light and moisture
Purchase confirms qualified researcher status
Inscrit sur la liste WADA Prohibited List S4 — any exposure may result in a positive test